home ver. 2.3. site index contact us

Message from the CEO
How We Work
Business Integrity
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

Management Biographies

MARGRIET GABRIEL-REGIS
Senior Vice President, Specialty Care Customer Group
Global Pharmaceutical Business
Schering-Plough Corporation
Kenilworth, New Jersey

Margriet Gabriel-Regis is senior vice president, Specialty Care Customer Group, for the Global Pharmaceutical Business of Schering-Plough Corporation.

Gabriel-Regis joined Schering-Plough in September 2003. She is responsible for developing and directing the implementation of comprehensive global marketing and sales strategies for the company's specialty care products. She also is responsible for managing the U.S. specialty product P&L, as well as strategic marketing and shared P&L accountability with the country operations for each global franchise. Additionally, she co-chairs both specialty development committees and is a member of the Pharmaceutical Leadership Board.

Prior to joining Schering-Plough, Gabriel-Regis held the position of group vice president - hospital and specialty for Pharmacia Corporation, where she managed P&L in the U.S. market and globally across five therapeutic franchises. She had joined Pharmacia Corporation in 2000 as group vice president, hospital. Previously, she was employed by Rhone-Poulenc Rorer, where she held various leadership roles in strategic planning and marketing. Gabriel-Regis began her career at Lederle International, which subsequently merged with Wyeth. During the course of her 13 years there, she held a number of increasingly responsible positions in finance, sales, marketing and regional and country management.

Gabriel-Regis earned a B.A. degree, summa cum laude, from McMaster University, Hamilton, Ontario, Canada, and an M.B.A. degree in finance from Pace University, New York.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.



Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough